Literature DB >> 30409255

Structural and Functional MRI in Familial Parkinson's Disease.

Avner Thaler1.   

Abstract

Between 10 and 15% of Parkinson disease (PD) cases can be traced to a genetically identified causative mutation which currently number over 40. This enables the study of both "at risk" populations for future development of PD and a unique sub-group of genetically determined patient population. Structural and functional magnetic imaging has the potential of assisting diagnosis, early detection and disease progression as it is relatively cheap and easy to implement. However, the large variety of imaging options and different analytical approaches hamper the pursuit of a unified imaging biomarker. This chapter details the current imaging options and summarizes the findings among both genetically determined patients with PD and their non-manifesting first degree relatives, speculating on possible compensational mechanisms while mapping future directions in order to better utilize MRI in the research of genetic PD.
© 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diffuse tensor imaging; Functional MRI; GBA; LRRK2; PARKIN; PINK1; Structural MRI

Mesh:

Year:  2018        PMID: 30409255     DOI: 10.1016/bs.irn.2018.09.005

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  3 in total

1.  Structural Connectivity and Emotion Recognition Impairment in Children and Adolescents with Chromosome 22q11.2 Deletion Syndrome.

Authors:  Ashley F P Sanders; Diana A Hobbs; Tracey A Knaus; Elliott A Beaton
Journal:  J Autism Dev Disord       Date:  2022-08-02

2.  Disrupted topological organization of resting-state functional brain networks in Parkinson's disease patients with glucocerebrosidase gene mutations.

Authors:  Yanbing Hou; Fei Feng; Lingyu Zhang; Ruwei Ou; Junyu Lin; Qiyong Gong; Huifang Shang
Journal:  Neuroradiology       Date:  2022-10-21       Impact factor: 2.995

Review 3.  Circuit imaging biomarkers in preclinical and prodromal Parkinson's disease.

Authors:  Sanne K Meles; Wolfgang H Oertel; Klaus L Leenders
Journal:  Mol Med       Date:  2021-09-16       Impact factor: 6.354

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.